Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 5/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434824 | 0.90 | LMNA (0.42) | PIK3CDAURKARPS6KB1AURKBMAP4K4 | |
| SCHEMBL4169793 | 0.88 | PIK3CD (0.49) | PIK3CDAURKARPS6KB1AURKBKDM4E | |
| SCHEMBL4176220 | 0.86 | LMNA (0.53) | PIK3CDAURKAAURKBMAP4K4DAPK3 | |
| SCHEMBL4433351 | 0.82 | MAP4K4 (0.41) | PIK3CDAURKAAURKBMAP4K4DAPK3 | |
| SCHEMBL4167501 | 0.82 | MAP4K4 (0.41) | PIK3CDEGFRAURKARPS6KB1AURKB | |
| SCHEMBL4173754 | 0.82 | LMNA (0.41) | PIK3CDAURKARPS6KB1CLK4LMNA | |
| SCHEMBL12015610 | 0.82 | MAP4K4 (0.41) | PIK3CDEGFRAURKARPS6KB1AURKB | |
| SCHEMBL4183370 | 0.82 | MAP4K4 (0.41) | PIK3CDEGFRAURKARPS6KB1AURKB | |
| SCHEMBL1598841 | 0.82 | MAP4K4 (0.41) | PIK3CDAURKAAURKBMAP4K4DAPK3 | |
| SCHEMBL16799113 | 0.81 | LMNA (0.39) | PIK3CDAURKARPS6KB1AURKBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-101715453-A | Heterogeneous ring compound and application thereof | AMGEN INC | 2010-05-26 | — | — | CN | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885EGFR 863/4885AURKA 867/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PIK3CD 16/4885EGFR 863/4885AURKA 867/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885EGFR 863/4885AURKA 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.